サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541267

月経前症候群治療市場レポート：薬剤タイプ、タイプ、流通チャネル、地域別、2024年～2032年

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 149 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.67円
月経前症候群治療市場レポート：薬剤タイプ、タイプ、流通チャネル、地域別、2024年～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 149 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

月経前症候群治療市場の世界市場規模は、2023年に13億9,700万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに18億9,080万米ドルに達し、2024年から2032年の間に3.3％の成長率（CAGR）を示すと予測しています。この市場を牽引するのは、患者の転帰と治療効率を高める精密医療への注目の高まり、医療へのアクセスを改善し治療の選択肢を広げる医療支出の増加、女性の労働参加率の増加などです。

月経前症候群治療市場分析：

主な市場促進要因：精密医療に対する需要の高まりは、ヘルスケア支出の増加とともに市場にプラスの影響を与えています。

主要市場動向：女性労働人口の増加と継続的な技術進歩が市場の成長を刺激しています。

地理的動向：北米は、強力なヘルスケア・インフラと堅調な経済により、医薬品をより手頃な価格で購入できるため、最大のセグメントを占めています。

競合情勢：月経前症候群治療業界の主要市場プレイヤーには、AbbVie Inc.、BASF SE、Bayer AG、Dr. Reddy's Laboratories Ltd.、Eli Lilly and Company、GlaxoSmithKline Plc.、H. Lundbeck A/S、Pfizer Inc.、SHIONOGI &Co.その他多数。

課題と機会：PMSに対する認識や理解の不足といった課題に直面する一方で、新たな治療法の開拓という機会にも遭遇しています。

月経前症候群治療市場の動向

精密医療への注目の高まり

IMARC Groupのレポートによると、世界の精密医療市場は2023年に752億米ドルに達しました。精密医療は、遺伝子プロファイル、ホルモンの状態、症状など患者の特性に合わせて医療介入を行うことができます。PMSの場合、症状や重症度は個人によって大きく異なるため、個別化アプローチにより、より的を絞った効果的な治療が可能になります。さらに、PMSに関連する遺伝的要因やバイオマーカーは、患者ごとに最も効果的な治療法を調整するのに役立ちます。その結果、治療成績が向上し、治療法の試行錯誤が少なくなります。これとは別に、患者の遺伝子や生理学的プロファイルに基づいて治療法を適合させることで、副作用を引き起こしにくい薬剤を選択することが、市場の成長を拡大しています。

ヘルスケア支出の増加

ヘルスケア支出の増加に伴い、PMSに悩む女性を含むより多くの人々が、PMSを適切に診断・治療できるプライマリケア医や婦人科医などの医療機関を受診するようになっています。加えて、ヘルスケア支出の高さは、ホルモン療法や抗うつ薬などの薬物療法や、認知行動療法や生活習慣の改善などの非薬物療法など、PMSの他の治療法へのアクセスの高さとも関連していることが多いです。高いヘルスケア支出は、より良いPMS治療法の発見に役立つ研究開発活動の機会を増やしています。メディケア・メディケイド・サービスセンターのウェブサイトに2024年に更新された内容によると、GDPに占める医療費の割合は2022年の17.3%から2032年には19.7%に拡大すると予測されています。

女性の労働参加の増加

世界銀行によれば、2023年の女性の労働力率は世界で49％です。より多くの女性が労働力になるにつれ、PMSの経済的な影響がより明白になってきています。その症状により、生産性、出勤率、職場でのパフォーマンスが脅かされます。このような影響を認識し、雇用主やヘルスケアプロバイダーは、PMSによる職場の混乱を軽減できる効果的な治療法を見つけることに、より意欲的になっています。さらに、企業はPMSのような生殖器系の健康問題へのサポートを含む職場ウェルネス・プログラムに投資しています。このようなプログラムでは、治療へのアクセス、症状のある日への柔軟なスケジュール調整、教育的リソースなどが提供され、これらすべてが、利用可能なPMS治療に対する認識と利用を高めています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の月経前症候群治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 鎮痛剤
    • 市場動向
    • 市場予測
  • 抗うつ薬
    • 市場動向
    • 市場予測
  • 経口避妊薬および卵巣抑制剤
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：タイプ別

  • 処方箋
    • 市場動向
    • 市場予測
  • OTC
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • ドラッグストアと薬局
    • 市場動向
    • 市場予測
  • オンラインストア
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
図表

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2023
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players
目次
Product Code: SR112024A4284

The global premenstrual syndrome treatment market size reached US$ 1,397.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,890.8 Million by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Analysis:

Major Market Drivers: The growing demand for precision medicine, along with the rising healthcare expenditure, is positively influencing the market.

Key Market Trends: Increasing female workforce participation and ongoing technological advancements are stimulating the growth of the market.

Geographical Trends: North America holds the largest segment because of its strong healthcare infrastructure and robust economy, which leads to greater affordability of medications.

Competitive Landscape: Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., SHIONOGI & Co. Ltd., among many others.

Challenges and Opportunities: While the market faces challenges like lack of awareness and understanding about PMS, it also encounters opportunities in the development of new treatment options.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

Analgesics

Antidepressants

Oral Contraceptives and Ovarian Suppression Agents

Others

Analgesics accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes analgesics, antidepressants, oral contraceptives and ovarian suppression agents, and others. According to the report, analgesics represents the largest segment.

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

Prescription

Over-the-Counter

Over-the-counter holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes prescription and over-the-counter. According to the report, over-the-counter accounts for the largest market share.

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Stores

Drugs stores and retail pharmacies represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, drug stores and retail pharmacies, and online stores. According to the report, drugs stores and retail pharmacies represent the largest segment.

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Premenstrual Syndrome Treatment Market News:

September 12, 2023: Vistagen, a late clinical-stage biopharmaceutical company announced positive results from exploratory phase 2A study of PH80 for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.

Key Questions Answered in This Report

  • 1. What was the size of the global premenstrual syndrome treatment market in 2023?
  • 2. What is the expected growth rate of the global premenstrual syndrome treatment market during 2024-2032?
  • 3. What are the key factors driving the global premenstrual syndrome treatment market?
  • 4. What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5. What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6. What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7. What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8. What are the key regions in the global premenstrual syndrome treatment market?
  • 9. Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis